BACKGROUND: Glycated hemoglobin (HbA(1c)) 6.5% has recently been recommended by the World Health Organization (WHO) and the American Diabetes Association (ADA) as an alternative diagnostic criterion for diabetes mellitus (DM). AIM: To evaluate HbA(1c) as an alternative to oral glucose tolerance test (OGTT) for diagnosis of DM and pre-diabetes and to find the optimal HbA(1c) cut-off points for DM and pre-diabetes in our population. SUBJECTS AND METHODS: The subjects were recruited from the Tromsø Study, performed for the 6th time in 2007-2008 with 12,984 participants. All subjects with HbA(1c) in the range 5.8-6.9% and a random sample of subjects with levels 5.3-5.7% were invited to an OGTT. RESULTS: Among 3476 subjects who completed the OGTT, 199 were diagnosed with DM. The best sensitivity (69.8%) and specificity (81.8%) were found at HbA(1c) 6.2%. For HbA(1c) 6.5% we found a sensitivity of 34.7% and specificity 97.1%. The best cut-off points for impaired fasting glucose (no.=314) and impaired glucose tolerance (no.=404) were found at HbA(1c) 5.9% and 6.0%, respectively. Pre-diabetes detected only by OGTT was associated with worse metabolic characteristics than pre-diabetes detected only by HbA(1c). CONCLUSIONS: The optimum HbA(1c) cutoff point for DM in our population was lower than that proposed by WHO and ADA. To establish more precisely the HbA(1c) levels predictive of micro- and macro-vascular complications, long-term prospective studies are needed. Population- specific optimum cut-off points may be necessary.
BACKGROUND: Glycated hemoglobin (HbA(1c)) 6.5% has recently been recommended by the World Health Organization (WHO) and the American Diabetes Association (ADA) as an alternative diagnostic criterion for diabetes mellitus (DM). AIM: To evaluate HbA(1c) as an alternative to oral glucose tolerance test (OGTT) for diagnosis of DM and pre-diabetes and to find the optimal HbA(1c) cut-off points for DM and pre-diabetes in our population. SUBJECTS AND METHODS: The subjects were recruited from the Tromsø Study, performed for the 6th time in 2007-2008 with 12,984 participants. All subjects with HbA(1c) in the range 5.8-6.9% and a random sample of subjects with levels 5.3-5.7% were invited to an OGTT. RESULTS: Among 3476 subjects who completed the OGTT, 199 were diagnosed with DM. The best sensitivity (69.8%) and specificity (81.8%) were found at HbA(1c) 6.2%. For HbA(1c) 6.5% we found a sensitivity of 34.7% and specificity 97.1%. The best cut-off points for impaired fasting glucose (no.=314) and impaired glucose tolerance (no.=404) were found at HbA(1c) 5.9% and 6.0%, respectively. Pre-diabetes detected only by OGTT was associated with worse metabolic characteristics than pre-diabetes detected only by HbA(1c). CONCLUSIONS: The optimum HbA(1c) cutoff point for DM in our population was lower than that proposed by WHO and ADA. To establish more precisely the HbA(1c) levels predictive of micro- and macro-vascular complications, long-term prospective studies are needed. Population- specific optimum cut-off points may be necessary.
Authors: Carlos Lorenzo; Lynne E Wagenknecht; Anthony J G Hanley; Marian J Rewers; Andrew J Karter; Steven M Haffner Journal: Diabetes Care Date: 2010-06-23 Impact factor: 19.112
Authors: Darin E Olson; Mary K Rhee; Kirsten Herrick; David C Ziemer; Jennifer G Twombly; Lawrence S Phillips Journal: Diabetes Care Date: 2010-07-16 Impact factor: 19.112
Authors: Lydie N Pani; Leslie Korenda; James B Meigs; Cynthia Driver; Shadi Chamany; Caroline S Fox; Lisa Sullivan; Ralph B D'Agostino; David M Nathan Journal: Diabetes Care Date: 2008-07-15 Impact factor: 17.152
Authors: Nayla Cristina do Vale Moreira; Renan M Montenegro; Haakon E Meyer; Bishwajit Bhowmik; Ibrahimu Mdala; Tasnima Siddiquee; Virgínia Oliveira Fernandes; Akhtar Hussain Journal: Int J Environ Res Public Health Date: 2019-09-26 Impact factor: 3.390
Authors: Paz Lopez-Doriga Ruiz; Laila Arnesdatter Hopstock; Anne Elise Eggen; Inger Njølstad; Guri Grimnes; Lars C Stene; Hanne L Gulseth Journal: BMJ Open Diabetes Res Care Date: 2021-11
Authors: Philippe B Katchunga; Patrick N Mirindi; Antoine S Kishabongo; Justin C Cikomola; Socrate Bwanamdogo; Jan Philippé; Marijn M Speeckaert; Joris R Delanghe Journal: Biochem Med (Zagreb) Date: 2015-10-15 Impact factor: 2.313
Authors: Ali Naseribafrouei; Bent-Martin Eliassen; Marita Melhus; Johan Svartberg; Ann Ragnhild Broderstad Journal: Int J Circumpolar Health Date: 2018-12 Impact factor: 1.228